Last edition
News about "Alecensa "
Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan
Chugai Pharmaceutical has received regulatory approval in Japan for the expanded use of Alecensa (alectinib) in advanced or recurrent ALK fusion-positive solid tumours, marking the world’s first tumour-agnostic approval for an ALK inhibitor.
Alecensa | 19/05/2026 | By News Bureau | 119
Genentech Receives Approval from FDA for Alecensa
Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
Alecensa | 22/04/2024 | By Aishwarya | 740
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy